Invention Grant
- Patent Title: PDCD1 as epigenetic marker for the identification of immune cells, in particular PD1+ cells
-
Application No.: US16758131Application Date: 2018-10-24
-
Publication No.: US11597975B2Publication Date: 2023-03-07
- Inventor: Sven Olek , Udo Baron
- Applicant: Epiontis GmbH
- Applicant Address: DE Berlin
- Assignee: Epiontis GmbH
- Current Assignee: Epiontis GmbH
- Current Assignee Address: DE Berlin
- Priority: DE102017125019.0 20171025
- International Application: PCT/EP2018/079184 WO 20181024
- International Announcement: WO2019/081590 WO 20190502
- Main IPC: C12Q1/6881
- IPC: C12Q1/6881

Abstract:
The present invention relates to a method, in particular an in vitro method, for identifying PD1+ cells, comprising analyzing the methylation status of at least one CpG position in the mammalian gene region for Programmed cell death 1 (PDCD1), wherein a demethylation or lack of methylation of said gene region is indicative for a PD1+ cell, when compared to a non-PD1+ cell. The analyses according to the invention can identify PD1+ cells on an epigenetic level and distinguish them from all other cells in complex samples, such as, for example, other blood or immune cells. The present invention furthermore provides an improved method for quantifying PD1+ cells, in particular in complex samples. The method can be performed without a step of purifying and/or enriching cells, preferably in whole blood and/or non-trypsinized tissue.
Public/Granted literature
- US20210123100A1 PDCD1 AS EPIGENETIC MARKER FOR THE IDENTIFICATION OF IMMUNE CELLS, IN PARTICULAR PD1+ CELLS Public/Granted day:2021-04-29
Information query
IPC分类: